These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8996520)
21. Phase II study with vinorelbine and cisplatin in advanced non-small cell lung cancer after failure of previous chemotherapy. Chen YM; Lee CS; Lin WC; Tsai CM; Perng RP J Chin Med Assoc; 2003 Apr; 66(4):241-6. PubMed ID: 12854877 [TBL] [Abstract][Full Text] [Related]
22. Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro. Wang H Nagoya J Med Sci; 2000 Nov; 63(3-4):129-37. PubMed ID: 11201987 [TBL] [Abstract][Full Text] [Related]
23. Angiocytotoxic therapy in human non-small cell lung cancer cell lines--advantage of combined effects of TNP-470 and SN-38. Satoh H; Ishikawa H; Fujimoto M; Fujiwara M; Yamashita YT; Yazawa T; Ohtsuka M; Hasegawa S; Kamma H Acta Oncol; 1998; 37(1):85-90. PubMed ID: 9572659 [TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Wozniak AJ; Crowley JJ; Balcerzak SP; Weiss GR; Spiridonidis CH; Baker LH; Albain KS; Kelly K; Taylor SA; Gandara DR; Livingston RB J Clin Oncol; 1998 Jul; 16(7):2459-65. PubMed ID: 9667264 [TBL] [Abstract][Full Text] [Related]
25. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Goa KL; Faulds D Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948 [TBL] [Abstract][Full Text] [Related]
26. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Le Chevalier T; Brisgand D; Soria JC; Douillard JY; Pujol JL; Ruffie P; Aberola V; Cigolari S Oncologist; 2001; 6 Suppl 1():8-11. PubMed ID: 11181998 [TBL] [Abstract][Full Text] [Related]
27. Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. Kobayashi M; Matsui K; Hirashima T; Nitta T; Sasada S; Tada T; Minakuchi K; Furukawa M; Ogata Y; Kawase I Int J Clin Oncol; 2006 Aug; 11(4):314-9. PubMed ID: 16937306 [TBL] [Abstract][Full Text] [Related]
28. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M; J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743 [TBL] [Abstract][Full Text] [Related]
29. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820 [TBL] [Abstract][Full Text] [Related]
30. Vinorelbine. A review of its antitumour activity in lung cancer. Sørensen JB Drugs; 1992; 44 Suppl 4():60-5; discussion 66-9. PubMed ID: 1283851 [TBL] [Abstract][Full Text] [Related]
31. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797 [TBL] [Abstract][Full Text] [Related]
32. Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer. Farhat FS; Ghosn MG; Kattan JG Cancer Chemother Pharmacol; 2015 Aug; 76(2):235-42. PubMed ID: 26024554 [TBL] [Abstract][Full Text] [Related]
33. [Lung carcinoma]. Sutani A; Kobayashi K Gan To Kagaku Ryoho; 2006 May; 33(5):590-4. PubMed ID: 16685153 [TBL] [Abstract][Full Text] [Related]
34. In vitro simulation study of individualized chemotherapy in lung cancer. Li C; Gemma A; Minegishi Y; Matsuda K; Seike Y; Noro R; Shionoya A; Kawakami A; Ogawa N; Kudoh S J Nippon Med Sch; 2007 Jun; 74(3):217-22. PubMed ID: 17625370 [TBL] [Abstract][Full Text] [Related]
35. Clinical studies of irinotecan alone and in combination with cisplatin. Fukuoka M; Masuda N Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018 [TBL] [Abstract][Full Text] [Related]
36. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine. Lokich JJ; Anderson N; Bern M; Coco F; Dow E Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721 [TBL] [Abstract][Full Text] [Related]
38. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239 [TBL] [Abstract][Full Text] [Related]
39. [Treatment of unresectable non-small-cell lung cancer]. Ueoka H Gan To Kagaku Ryoho; 2000 Mar; 27(3):356-61. PubMed ID: 10740628 [TBL] [Abstract][Full Text] [Related]
40. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Wakelee HA; Middleton G; Dunlop D; Ramlau R; Leighl N; Hao D; Lopez-Anaya A; Zatloukal P; Jacobs CD Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]